16 news items
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
REGN
31 May 24
of the foregoing; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN
31 May 24
on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
REGN
31 May 24
, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
REGN
31 May 24
); the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
REGN
23 May 24
, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution
t4oqt5i2rrl8w 3bey
REGN
20 May 24
crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our
et4tktfbzwvia34jn4d34hbgkt5mprsd82
REGN
20 May 24
) and Regeneron's Product Candidates (such as itepekimab); the ability of Regeneron's collaborators, licensees, suppliers, or other third parties
oc26frsps 2616je6s4tpaaxh4njratwang1lvywciv9pdjx
REGN
13 May 24
(such as Dupixent) and Regeneron's Product Candidates; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties
0c0tgtrpurp0a7b5s77tlfw539si14bztj738auwje8fj1v2n4z
REGN
8 May 24
of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging
2uiw73xx2fuplemxik29 j4ypfkwwjz3seq7n9j3697w2xug2sn0
REGN
2 May 24
candidates; the ability of Regeneron's collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging
4f8h8u12133yojunors3jk2mfnasu7gcj3mt dr0pmcz07974p
REGN
29 Apr 24
of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling
1f7re6pzm
REGN
22 Apr 24
approval of Regeneron's Products and Regeneron's Product Candidates (such as DB-OTO); the ability of Regeneron's collaborators, licensees, suppliers
zmtih8xs39mqv9z xu3w9d1q0pkrh42dabymjap4
REGN
7 Apr 24
of Regeneron's Products and Regeneron's Product Candidates (such as linvoseltamab); the ability of Regeneron's collaborators, licensees, suppliers
z763h35
REGN
25 Mar 24
Products and Regeneron's Product Candidates; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable
w926z392oqavfvo1
REGN
11 Mar 24
for Regeneron's Products; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling
66148ixo9pjr
REGN
8 Mar 24
indications for Regeneron's Products; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable
- Prev
- 1
- Next